Foundation Medicine (NASDAQ:FMI) will be posting its quarterly earnings results after the market closes on Tuesday, February 20th. Analysts expect Foundation Medicine to post earnings of ($0.99) per share for the quarter.
Foundation Medicine (NASDAQ FMI) opened at $63.70 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. Foundation Medicine has a 12 month low of $22.40 and a 12 month high of $75.20. The stock has a market capitalization of $2,310.00, a P/E ratio of -14.25 and a beta of -0.03.
In related news, insider Vincent A. Miller sold 4,400 shares of Foundation Medicine stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $330,000.00. Following the sale, the insider now directly owns 97,722 shares in the company, valued at $7,329,150. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Evan/ Fa Jones sold 6,500 shares of Foundation Medicine stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $60.66, for a total value of $394,290.00. Following the sale, the director now owns 19,652 shares in the company, valued at $1,192,090.32. The disclosure for this sale can be found here. Insiders have sold 228,717 shares of company stock worth $14,987,592 over the last three months. Insiders own 2.70% of the company’s stock.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.